Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
OS Therapies said Phase 2b results in herlystic(TM)-treated pulmonary metastatic osteosarcoma patients showed a statistically significant final three-year overall survival benefit.
OS Therapies (OSTX) announced a statistically significant benefit for OST-HER2-treated patients in interim 3-year overall survival analysis from its Phase 2b pulmonary metastatic osteosarcoma trial.